Tag: conferences

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

NEW CANAAN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OTCQX: NLCP) (“NewLake or “the Company”), a leading provider of real estate capital to state-licensed cannabis operators, today announced that management will participate in the following June 2026 conferences.

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”).

Accelerating cleantech economic growth and sustainability initiatives through innovation, collaboration and education

COLUMBUS, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Root, Inc. (NASDAQ: ROOT), a leading technology company powering insurance solutions and the parent company of Root Insurance, today announced that it will participate in three upcoming investor conferences in New York City and virtually.

New York, N.Y., Aug. 13, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced its attendance at several upcoming industry focused investor events.

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.